Katy M. Toale is a clinical pharmacy specialist at the University of Texas MD Anderson Cancer Center in Houston, where Gina Butler and Goley Richardson are associate directors of nursing programs, Jeff Beno is a senior health care systems engineer, and Neetha Jawe is a senior clinical quality improvement consultant. The authors acknowledge Dawn Chalaire, associate director for editing services, Research Medical Library, University of Texas MD Anderson Cancer Center, for her editorial assistance. Contact author: Katy M. Toale,
Am J Nurs. 2024 Jun 1;124(6):40-46. doi: 10.1097/01.NAJ.0001023968.05082.57. Epub 2024 May 23.
Unfractionated heparin (UFH) is a high-risk medication that can cause bleeding and/or thrombotic complications if not managed appropriately. Between January and July 2019, our institution experienced a high number of patient safety events related to UFH infusion for the treatment of venous thromboembolism (VTE).
The aim of this quality improvement (QI) initiative was to prevent these safety events by improving compliance with our institution's nurse-driven VTE UFH infusion protocol.
Baseline data for patients on the VTE UFH protocol were collected to identify improvement opportunities. Compliance with eight standards of care related to the VTE UFH infusion protocol was measured. Time to first therapeutic activated partial thromboplastin time (aPTT) was recorded to assess the benefit of improved compliance.
Institutional policy updates were made to clarify the management of UFH infusions and documentation in the electronic health record. A multidisciplinary workgroup implemented order set changes, nursing communication orders, UFH infusion reports, and a nursing education module to promote compliance with the protocol.
The overall rate of compliance with the VTE UFH infusion protocol increased from 79.4% at baseline to 85.2% following implementation of the QI initiative, and the median time to first therapeutic aPTT decreased from 831.5 minutes to 808 minutes over the same period.
A multidisciplinary initiative to address improvement opportunities in a nurse-driven UFH protocol for VTE treatment increased compliance with the protocol and decreased the time to first therapeutic aPTT.
未分级肝素(UFH)是一种高风险药物,如果管理不当,可能会导致出血和/或血栓并发症。在 2019 年 1 月至 7 月期间,我们机构发生了多起与 UFH 输注治疗静脉血栓栓塞症(VTE)相关的患者安全事件。
本质量改进(QI)计划的目的是通过提高我们机构护士驱动的 VTE UFH 输注方案的依从性来预防这些安全事件。
收集 VTE UFH 方案患者的基线数据,以确定改进机会。测量与 VTE UFH 输注方案相关的八项护理标准的依从性。记录首次治疗性活化部分凝血活酶时间(aPTT)的时间,以评估提高依从性的益处。
对机构政策进行了更新,以澄清 UFH 输注的管理和电子病历中的记录。一个多学科工作组实施了医嘱集变更、护理沟通医嘱、UFH 输注报告和护理教育模块,以促进对方案的依从性。
在实施 QI 计划后,VTE UFH 输注方案的总体依从率从基线时的 79.4%提高到 85.2%,同时,首次治疗性 aPTT 的中位数时间从 831.5 分钟缩短至 808 分钟。
一项针对护士驱动的 VTE 治疗 UFH 方案中改进机会的多学科举措,提高了方案的依从性,并缩短了首次治疗性 aPTT 的时间。